lapatinib has been researched along with Thrombocytopenia in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baselga, J; Blackwell, K; Diéras, V; Gianni, L; Green, M; Hoersch, S; Krop, IE; Miles, D; Pegram, M; Verma, S; Welslau, M; Xu, J | 1 |
| Badovinac-Crnjevic, T; Ferrero, JM; Hoersch, S; Kim, SB; Krop, IE; LoRusso, PM; Martin, AG; Smitt, M; Wildiers, H | 1 |
| Cloughesy, TF; Faiq, N; Green, R; Green, S; Hu, J; Lai, A; Mellinghoff, I; Nghiemphu, PL; Yu, A | 1 |
| Cathomas, R; von Moos, R | 1 |
3 trial(s) available for lapatinib and Thrombocytopenia
| Article | Year |
|---|---|
Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Aged, 80 and over; Anemia; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Breast Neoplasms; Breast Neoplasms, Male; Bridged-Ring Compounds; Capecitabine; Diarrhea; Disease-Free Survival; Female; Hand-Foot Syndrome; Humans; Lapatinib; Male; Maytansine; Middle Aged; Quinazolines; Receptor, ErbB-2; Response Evaluation Criteria in Solid Tumors; Retreatment; Survival Rate; Taxoids; Thrombocytopenia; Trastuzumab; Vomiting; Young Adult | 2017 |
Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial.
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Bridged-Ring Compounds; Chemotherapy-Induced Febrile Neutropenia; Diarrhea; Early Termination of Clinical Trials; Female; Hemorrhage; Humans; Lapatinib; Male; Maytansine; Middle Aged; Neoplasm Metastasis; Neutropenia; Practice Patterns, Physicians'; Quinazolines; Receptor, ErbB-2; Retreatment; Survival Rate; Taxoids; Thrombocytopenia; Trastuzumab | 2017 |
Report of safety of pulse dosing of lapatinib with temozolomide and radiation therapy for newly-diagnosed glioblastoma in a pilot phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Drug Administration Schedule; Female; Glioblastoma; Humans; Karnofsky Performance Status; Lapatinib; Male; Middle Aged; Necrosis; Pilot Projects; Quinazolines; Temozolomide; Thrombocytopenia; Treatment Outcome | 2017 |
1 other study(ies) available for lapatinib and Thrombocytopenia
| Article | Year |
|---|---|
Severe drug-induced thrombocytopenia after treatment with trastuzumab but not with lapatinib.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Carcinoembryonic Antigen; Carcinoma, Ductal, Breast; Deoxycytidine; Female; Fluorouracil; Humans; Immunohistochemistry; Lapatinib; Middle Aged; Mucin-1; Quinazolines; Receptor, ErbB-2; Thrombocytopenia; Trastuzumab | 2009 |